Pharmaceutical Segment for the First Half

Increased in sales and operating income YoY

Strong growth despite severe NHI drug price reduction

Breakdown

 • NHI drug price reduction JPY -6.0 billion

 • Sales growth of SYCREST and Bilanoa

 • Cost reduction JPY 3.8 billion

 ▸ In-house manufacturing products

 ▸ Favorable variance from inventory reevaluation due to a manufacturing site shutdown

 • Operating income excluding KM Biologics JPY 4.9 billion